Investors Anticipate Biotech Rebound in 2026 as Market Conditions Improve
Investors are looking toward a potential rebound in the U.S. biotech sector in 2026, with expectations of more IPOs amid renewed deal-making and lower interest rates, despite lingering uncertainties.